Drug Development

Each year many new prescription drugs are approved by the Food and Drug Administration (FDA). The process of developing and bringing new drugs to market is important for primary care physicians to understand. A drug must undergo rigorous testing prior to marketing to and medical use by the general public. The process starts with preclinical testing. For drugs that appear safe, an investigational new drug application is filed with the FDA. If approved, clinical trials begin with phase 1 studies that focus on safety and pharmacology. Phase 2 studies examine the effectiveness of the compound. Phase 3 is the final step before submitting a new drug application (NDA) to the FDA. An NDA contains all the information obtained during all phases of testing. Phase 4 studies, or postmarketing studies, are conducted after a product is approved. Recent changes in legislation have streamlined the approval process. Critics contend that these changes have compromised public safety, resulting in the need to recall several products from the market. Proponents claim that changes in the approval process help patients with debilitating diseases, such as acquired immunodeficiency syndrome, that were previously denied critical medication because of bureaucratic regulations.

The worldwide market for medication disclosure in pharmaceuticals came to about $25.0 billion in 2013. This market is relied upon to reach $29.6 billion in 2014 and $79.8 billion in 2019, with a compound yearly development rate (CAGR) of 22.0% for the time of 2014 to 2019.

 

  • Discovery and Development
  • Preclinical Research
  • Clinical Research
  • FDA Review
  • Drug Development Research
  • Drug Characterisation
  • Drug Designing and Targeting

Related Conference of Drug Development

December 02-03, 2020

2nd International Conference on Bio-Pharmaceuticals

Auckland, Newzealand
December 07-08, 2020

International Conference on Biotechnology and Healthcare

Auckland, Newzealand
December 16-16, 2020

21st World Conference on Pharmaceutical Chemistry and Drug Design

Singapore City, Singapore
December 16-16, 2020

22nd World Congress on Pharmacology, Nursing and Healthcare

Algeria, Algeria
January 22-23, 2021

1 st Global Summit on Generic Drugs and Quality Control

Prague, Czech Republic
January 22-23, 2021

1 st World Congress on Rare Diseases & Orphan Drugs

Prague, Czech Republic
February 26-27, 2021

2nd Annual Congress on Antibiotics and Bacterial Infections

Geneva, Switzerland
March 10-11, 2021

6th Pharmaceutical Chemistry Conference

Paris, France
March 16-17, 2021

14th Global Pharmacovigilance And Clinical Trials Summit

Albufeira, Portugal
April 11-12, 2021

2 nd World Pharma Expo

Tokyo, Japan
April 12-13, 2021

2nd International Conference on Biosimilars & Pharmaceuticals

Auckland, Newzealand
April 28-29, 2021

31st Annual European Pharma Congress

London, UK
April 28-29, 2021

14th European Biosimilars Congress

London, UK
May 10-11, 2021

20th Annual Meet on Pharmaceutical Sciences

Yokohama, Japan
May 17-18, 2021

8th European Biopharma Congress

Prague, Czech Republic
May 19-20, 2021

36th World Pharmacology and Therapeutics Forum

Singapore, Singapore
June 07-08, 2021

2rd European Conference on Pharmacovigilance and Drug Safety

Prague, Czech Republic
July 10-11, 2021

2 nd Pharma Expo China

Tokyo, Japan
August 16-17, 2021

Global summit on Cosmetic & Reconstructive Surgery

Tokyo, Japan
August 16-17, 2021

34rd World Congress on Pharmacology

London, UK
October 29-30, 2021

14th World Drug Delivery Summit

Vancouver, Canada
October 29-30, 2021

12th Annual Biomarkers and Clinical Research Congress

Vancouver, Canada

Drug Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in